Zealand Pharma, a Denmark-based drugmaker, will acquire “substantially all” of Valeritas’ assets for $23 million, according to a Feb. 9 news release.
Valeritas manufactures the V-Go wearable insulin delivery device.
The company said it will continue operations as normal during the transaction with Zealand.
Read the full news release here.
More articles on supply chain:
Coronavirus will cost Boston Scientific $10M to $40M in Q1, company says
Premier acquires New York Hospital Association’s GPO
Tennessee hospital lab manager quits, says hospital regularly ran out of critical supplies
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.